目录
更新日期:2025年10月17日
姓 名 刘莉 性 别
民 族 汉族 导师层次 博士导师
技术职称 主任医师 导师类型 学术&专业型
最后学历 博士研究生毕业 最后学位 医学博士学位
行政职务 科室主任 Email 18602062738@163.com
工作单位 南方医科大学南方医院 邮政编码 510515
个人简介

    刘莉,1972年出生,南方医科大学南方医院健康管理中心主任,医工交叉拓展研究院执行院长、主任医师、教授,博士生导师。“珠江学者”特聘教授、广东省杰出医学人才、广东省特支计划千百万工程领军人才。现任中华医学会健康管理学分会常委、广东省健康体检管理专业质控中心主任、中国抗癌协会肿瘤人工智能专委会常委,中国抗癌协会肝癌专委会委员,中国医院协会疾病与健康管理分会常委等。

    主要围绕肝癌的基础、临床、转化、人工智能、精准医疗等方面开展系列研究。迄今主持国家重点研发计划、国家自然科学基金项目等多项课题,科研经费充足。在Gastroenterology 、Clin Cancer Res、Advanced Science、Oncogene、Ann Oncol等期刊发表多篇SCI论著,作为第二完成人获广东省自然科学奖一等奖1项、湖北省科技进步奖一等奖1项。

研究领域

    肝癌的基础及临床研究;医疗大数据的整合及转化研究。

个人成果

1. Xiao L#, Zeng L#, Wang J#, Hong C#, Zhang Z#, Wu C, Cui H, Li Y, Li R, Liang S, Deng Q, Li W, Zou X*, Ma P*, Liu L*(co-corresponding author). Development and Validation of Machine Learning-Based Marker for Early Detection and Prognosis Stratification of Nonalcoholic Fatty Liver Disease. Adv Sci (Weinh). 2025 Sep;12(33):e10527. (IF:14.1)

2. Peng J#, Wang J#, Zhu H#, Jiang P#, Xia J, Cui H, Hong C, Zeng L, Li R, Li Y, Liang S, Deng Q, Deng H, Xu H, Dong H*, Xiao L*, Liu L*(co-corresponding author). Three-dimensional multimodal imaging for predicting early recurrence of hepatocellular carcinoma after surgical resection. J Adv Res. 2025 Jun 16:S2090-1232(25)00440-0. doi: 10.1016/j.jare.2025.06.031. Epub ahead of print. PMID: 40533057.(IF:13.0)

3.Zeng L#, Ma P#, Li Z#, Liang S#, Wu C#, Hong C, Li Y, Cui H, Li R, Wang J, He J, Li W, Xiao L*, Liu L*(co-corresponding author). Multimodal Machine Learning-Based Marker Enables Early Detection and Prognosis Prediction for Hyperuricemia. Adv Sci (Weinh). 2024 Sep;11(34):e2404047. doi: 10.1002/advs.202404047. Epub 2024 Jul 8. PMID: 38976552; PMCID: PMC11425915.(IF:14.1)

4.Liu C#, Zhou X#, Zeng H#, Yu J, Li W, Zhang W, Liao Y, Wang H, Liu L*(co-corresponding author). Endoplasmic Reticulum Stress Potentiates the Immunosuppressive Microenvironment in Hepatocellular Carcinoma by Promoting the Release of SNHG6-Enriched Small Extracellular Vesicles. Cancer Immunol Res. 2024 Sep 3;12(9):1184-1201.(IF:8.2)

5. Zou X #, Zhang D #, Song Y #, Liu S, Long Q, Yao L, Li W, Duan Z, Wu D*, Liu L*(co-corresponding author). HRG switches TNFR1-mediated cell survival to apoptosis in Hepatocellular Carcinoma. Theranostics 2020, 10(23): 10434-47.(IF:11.556)

6.Liu L(co-first author), Bai X#, Wang J#, Tang XR#, Wu DH, Du SS, Du XJ, Zhang YW, Zhu HB,Fang Y, Guo ZQ, Zeng Q, Guo XJ, Liu Z, Dong ZY* : Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer. Clinical cancer research 2019, 25(24):7413-7423.(IF:12.531)

7.Xiao L #, Zhang W #, Gong M #, Zhang Y #, Chen L #, Zhu H , Hu C , Kang P, Liu L*. (corresponding author), Zhu H*. Development and validation of the HNC-LL score for predicting the severity of coronavirus disease 2019. EBioMedicine 2020, 57:102880.(IF:8.143)

8.​Liu C#, Zhou X#, Long Q#, Zeng H, Sun Q, Chen Y, Wu D* , Liu L*(co-corresponding author). Small extracellular vesicles containing miR-30a-3p attenuate the migration and invasion of hepatocellular carcinoma by targeting SNAP23 gene. Oncogene 2021, 40(2):233-245.(IF:9.867)

 
9. Hua S, Lei L, Deng L, Weng X, Liu C, Qi X, Wang S, Zhang D, Zou X, Cao C, Liu L*(co-corresponding author),Wu D*. miR-139-5p inhibits aerobic glycolysis, cell proliferation, migration, and invasion in hepatocellular carcinoma via a reciprocal regulatory interaction with ETS1. Oncogene 2018,37(12):1624-1636. (IF= 9.867)
 
10.Cao C#, Zhang T#, Zhang D#, Xie L#, Zou X, Lei L, Wu D* , Liu L*(co-corresponding author) . The long non-coding RNA, SNHG6-003, functions as a competing endogenous RNA to promote the progression of hepatocellular carcinoma. Oncogene 2017, 36(8):1112-1122.(IF:9.867)
 
11.Cao C#, Sun J#, Zhang D, Guo X, Xie L, Li X, Wu D* , Liu L*(co-corresponding author) . The long intergenic noncoding RNA UFC1, a target of MicroRNA 34a, interacts with the mRNA stabilizing protein HuR to increase levels of β-catenin in HCC cells. Gastroenterology 2015,148(2):415-426.e418.(IF:22.682)